Check out this timely review article co-authored with Dr. Santangeli, VT Program Director at #clevelandclinic currently in press during Sudden Cardiac Arrest Awareness month #epeeps. The field of VT ablation needs to expand dramatically - see the estimated number of epicardial VT ablations we should be considering in the US annually (probably > 20x the current annual volume). https://lnkd.in/gE-PEqc4
关于我们
Corfigo’s mission, simply described, is embedded in the translation of our company name: (‘cor’: heart + ‘figo’: fix, repair, in Latin). We aim to fix hearts that are not working properly, using creativity and technology. Corfigo has developed a potent, novel cryoablation platform to overcome the barriers of current ablation technologies to treat serious heart rhythm disorders.
- 网站
-
https://www.corfigo.com
CorFigo, Inc. 的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 2-10 人
- 总部
- Montclair，New Jersey
- 类型
- 私人持股
- 创立
- 2015
地点
-
主要
获取路线
75 Montclair Ave
US，New Jersey，Montclair
CorFigo, Inc. 员工
动态
-
Very proud of our collaboration with the Cleveland Clinic and the AFIC lab over the past 2 years and our pretty amazing pre-clinical results: https://t.co/x1mnKlCJOG. We can't wait to finish prototyping and to begin testing the HeartPad? Ribbon - our all-in-one device that will be used to ablate atrial or ventricular targets epicardially on a full, beating heart. The first and only cryoablation platform based on liquid helium with a unique ablation element design and function - pre-clinical data suggests this to be the only tech with the ability to ablate straight through epicardial fat tissue and despite cardiac chamber warm blood flow (heat sink).
Efficacy of Balloon Expandable Extreme-Low Temperature Ventricular Epicardial Cryoablation: A Preclinical Proof of Concept Evaluation
heartrhythmjournal.com
-
We are excited to share that we are moving into our next pre-clinical phase - developing our all-in-one XLT cryoablation device, the HeartPad? Ribbon. This adjustable-length epicardial ablation device will ultimately be used to ablate cardiac tissue in open surgical and minimal access settings, and achieve temperatures colder than -250C.
-